Controlled trial of the effect of cortisone acetate in status asthmaticusSystemic corticosteroids for acute exacerbations of chronic obstructive pulmonary diseaseEffect of beclomethasone dipropionate delivered by aerosol in patients with asthmaPotential adverse effects of inhaled corticosteroidsGlobal strategy for the diagnosis, management and prevention of COPD: 2011 updateGlucocorticosteroids: current and future directionsRelevance of pharmacokinetics and pharmacodynamics of inhaled corticosteroids to asthmaSafety of inhaled corticosteroids: room for improvementAerosol drug delivery: developments in device design and clinical useSystemic exposure to fluticasone MDI delivered through antistatic chambersGrowth of preschool children at high risk for asthma 2 years after discontinuation of fluticasoneDose–response relationship of inhaled budesonide in adult asthma: a meta-analysisClinical dose–response relationship of fluticasone propionate in adults with asthmaDose response of inhaled corticosteroids in children with persistent asthma: a systematic reviewDecreased response to inhaled steroids in overweight and obese asthmatic childrenVitamin D levels, lung function and steroid response in adult asthmaEfficacy of inhaled corticosteroids in infants and preschoolers with recurrent wheezing and asthma: a systematic review with meta-analysisAnti-leukotriene agents compared to inhaled corticosteroids in the management of recurrent and/or chronic asthma in adults and childrenInhaled corticosteroids versus sodium cromoglycate in children and adults with asthmaAmerican Academy of Allergy, Asthma and Immunology; American College of Allergy, Asthma and Immunology; Joint Council of Allergy, Asthma and Immunology. doi: 10.1371/journal.pone.0201330. Inhaled corticosteroids work by preventing certain cells in the lungs and breathing passages from releasing substances that cause asthma symptoms. Although VHCs may be used with MDI for patients who cannot coordinate actuation and inhalation, they can alter the therapeutic index, particularly the newer antistatic devices (All of the current ICSs should be used cautiously with potent inhibitors of cytochrome P450 3A4 isoenzymes (CYP 3A4), such as ritonavir, itraconazole, and ketoconazole (Existing data from numerous clinical trials support the current recommendations from national and global asthma and COPD guidelines (New ICSs with prolonged activity for once-daily dosing even in patients with more moderate to severe asthma are undergoing clinical trials in asthma and COPD with and without a once-daily LABA (The authors thank Gretchen Hugen for assistance with manuscript preparation.Supported in part by National Institutes of Health Public Health Services Research Grants HL-64288, HL-51834, AI-90052, HL-75416, HL-87811, ES-18181, HL-98075; by the Colorado Cancer, Cardiovascular and Pulmonary Disease Program; and by Colorado CTSA grant 1 UL1 RR025780 from the National Institutes of Health and the National Center for Research Resources.This article is part of the American Journal of Critical Care and Respiratory Medicine Modern Pharmacotherapy of Lung Disease Series 2013.Click to see any corrections or updates and to confirm this is the authentic version of record
GENOMIC MECHANISMS OF CORTICOSTEROID ACTIONS Inhaled corticosteroids suppress airway inflammation, which is responsible for asthma-associated changes of the airway vasculature. Topical corticosteroids have a local effect. GENOMIC MECHANISMS OF CORTICOSTEROID ACTIONS Inhaled corticosteroids suppress airway inflammation, which is responsible for asthma-associated changes of the airway vasculature. They are used to help prevent the symptoms of asthma. Inhaled corticosteroids have considerably fewer systemic effects than oral corticosteroids, but adverse effects including adrenal suppression have been reported. Mechanism Of Action Corticosteroids have many cell- and tissue-specific antiinflammatory effects that have been extensively described ( 8 ). 2001;3(7):509-37. doi: 10.2165/00128072-200103070-00003.Br J Pharmacol.
Correspondence and requests for reprints should be addressed to Stanley J. Szefler, M.D., National Jewish Health, 1400 Jackson Street, Room J304 Molly Blank Building, Denver, Colorado 80206.